Clinical TrialAug 10, 2026, 04:12 PM
Purple Biotech's IM1240 to Enter Clinic 2027; $6.1M Cash
AI Summary
Purple Biotech presented its CAPTN-3 tri-specific antibody platform, designed for safer and broader tumor killing by activating both T cells and NK cells with a masking technology. Its lead program, IM1240, is expected to enter clinical trials in 2027, demonstrating strong anti-tumor activity and a 300x improved safety profile in preclinical studies. The company reported $6.1 million in cash as of June 30, 2026, with a runway until mid-2027.
Key Highlights
- Lead program IM1240 (CAPTN-3 tri-specific antibody) expected to enter clinic in 2027.
- CAPTN-3 platform activates T cells and NK cells with masking technology for tumor-selective activation.
- IM1240 demonstrated strong anti-tumor activity and 300x improved safety in preclinical studies.
- Second program, IM1305 (cappedCD3xTROP2xNKG2A), is in preclinical development.
- Cash balance was $6.1M as of June 30, 2026, with a runway until mid-2027.
- IM1240 Phase 1/2 study planned to initiate H1 2027, with P1 results expected H1 2028.
- Comparable masked TCE programs secured over $1B in deals at preclinical stage.
Price Impact
More from PPBT